Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 DISEASE NETWORK REGISTRY PROJECTS LOGIN
 
 
  
Experimental Rx -
--->Nyheter
[-]Prosjektet
--->Sponsor
--->[+]Hovedstyre
--->[-]Writing Committee Strategic ...
--->Dates
--->[+]Scientific Review Committee
--->Sentralkoordinering
--->Språkkoordinering
--->Fellowship Programme
--->[-]Constitution
--->Article 1
--->Article 2
--->Article 3
--->Article 4
--->Article 5
--->Article 6
--->Article 7
--->Article 8
--->Article 9
--->Article 10
--->Article 11
--->Article 12
--->Documents
--->[+]Voting/Nomination
--->[+]Medlemskap
[-]Foskningssteder
--->[+]Østerrike
--->[+]Belgia
--->[+]Tsjekkiske republikk
--->[+]Danmark
--->[+]Finland
--->[+]Frankrike
--->[+]Tyskland
--->[+]Ireland
--->[+]Italia
--->[+]Nederland
--->[+]Norge
--->[+]Poland
--->[+]Portugal
--->[+]Russia
--->[+]Spania
--->[+]Sverige
--->[+]Sweits
--->[-]Storbrittania
--->Coordination
--->HD Associations
--->Links
--->[+]UKHDN
--->Standard of Care
--->Aberdeen
--->[+]Ayr
--->Belfast
--->Birmingham
--->[+]Blandford Forum
--->Bristol
--->Cambridge
--->Cardiff
--->Dundee
--->Edinburgh
--->Exeter
--->Fife
--->Forth Valley
--->Glasgow
--->Gloucester
--->Hull
--->Inverness
--->Launceston
--->Leeds
--->Leicester
--->Liverpool
--->London - Guy's Hospital
--->London - Hammersmith
--->London - NHNN
--->London - Royal Hospital
--->London - St. George´s
--->Manchester
--->Newcastle-Upon-Tyne
--->[+]Northampton
--->Nottingham
--->Oxford
--->[+]Plymouth
--->Poole
--->Preston
--->Reading
--->[+]Sheffield
--->Southampton
--->Stoke-on-Trent
--->Swindon
--->Wrexham
--->[+]Utenfor Europa
[-]Arbeidsgrupper
--->[+]Advanced HD
--->[-]Behavioural Phenotype
--->Dates
--->[+]Meetings
--->[+]Psycho appr. & interv. Sub...
--->[+]Biologisk Modifiserende Fakto...
--->[+]Biomarkører
--->[+]Brain and Tissue Banking
--->[+]Kognitiv Fenotype
--->[+]Environmental Modifiers
--->[-]Funksjonell Vurdering
--->Dates
--->[+]Meetings
--->[+]Genetisk Testing
--->[+]Genetisk Modifiserende Fakto...
--->[+]Helseøkonomi
--->[+]Bildteknikk
--->[+]Juvenile HS
--->[+]Motorisk Fenotype
--->[+]Neurobeskyttende Behandlin...
--->[-]Fysioterapi
--->Dates
--->[+]Meetings
--->[+]Livskvalitet
--->[+]Omsorgsstandard
--->[+]Kirurgiske Terapaier
--->[+]Symptomatiske Behandling
--->[+]Young Adults
[-]Begivigheter
--->[+]EHDN 2016
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[+]EHDN 2010
--->[+]EHDN 2008
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[+]EHDN 2005
--->[+]EHDN 2004
[+]Kontakt
--->Jobb Tilbud
datobeskrivelsestørrelseforfatter dokument 
04.08.26In vivo efficacy of (CUG)n oligonucleotides to treat HD32 kBanonymousapplication/mswordp02-in-vivo-efficacy-oligonucleotides 
04.08.26Antisense oligonucleotide mediated transcript reduction and modulation – the European approach to develop a therapy for Huntington Disease32 kBanonymousapplication/mswordp01-antisense-oligonucleotide-transcript 
04.08.26Reducing toxic n-terminal Huntingtin fragments in HD using exon skipping32 kBanonymousapplication/mswordp03-exon-skipping 
04.08.26A Huntingtin peptide inhibits polyQ-hHtt associated defects32 kBanonymousapplication/mswordp04-polyq-hhtt-associated-defects 
04.08.26Astrocytes affect neuroprotection: Glatiramer acetate in Huntington`s Disease therapy32 kBanonymousapplication/mswordp07-glatiramer-acetate 
04.08.26Olesoxime improves specific features of the HD pathology32 kBanonymousapplication/mswordp06-olesoxime 
04.08.26Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia – an anti-inflammatory therapy in neurodegenerative disease?!32 kBanonymousapplication/mswordp08-analysis-of-nrf2 

Fil innholder 7 dokumenter.
about us | privacy statement | disclaimer | terms of use